Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

Authors:

Abstract
No abstract available
Funding Information
  • Novo Nordisk A/S, Bagsværd, Denmark